title: Study of the functional share of lysosomal cathepsins by the development of specific inhibitors.
abstract: To analyze the functional share of individual cathepsins, we developed powerful and specific inhibitors for individual cathepsins using computer graphics of substrate binding pockets based on X-ray crystallography. These new inhibitors were named CLIK group. Epoxy succinate peptide derivatives, CLIK-066, 088, 112, 121, 148, 181, 185 and 187, are typical specific inhibitors for cathepsin L. Aldehyde derivatives CLIK-060 and CLIK-164 showed specific inhibition against cathepsin S and cathepsin K, respectively. We found that pyridoxal phosphate (PLP), a coenzyme form of vitamin B6, inhibits all cathepsins and also new artificially synthesized pyridoxal derivatives, CLIK-071 and -072, in which the phosphate esters of PLP were replaced by propionic acid, exhibited strong inhibition for cathepsins. Furthermore, CLIK-071 was easy to incorporate into cells and showed powerful inhibition for intracellular cathepsins. Using these selective inhibitors, the allotment of individual cathepsin functions in cells has been studied as follows. Cathepsin L and/or K participate in bone resorption based on bone type-1 collagen degradation and the L-type protease inhibitors suppressed the bone resorption. Cathepsins B and S participate in antigen presentations based on antigen processing and invariant chain degradation, respectively. Also cathepsin L participates in cell apoptosis mediated by caspase III activation.
authors.affiliation: Institute for Health Sciences, Tokushima Bunri University, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Katunuma
authors.forename: A
authors.initials: A
authors.lastname: Matsui
authors.forename: T
authors.initials: T
authors.lastname: Kakegawa
authors.forename: E
authors.initials: E
authors.lastname: Murata
authors.forename: T
authors.initials: T
authors.lastname: Asao
authors.forename: Y
authors.initials: Y
authors.lastname: Ohba
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D001862:Bone Resorption / Q000517:prevention & control; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D020134:Catalytic Domain; D056668:Cathepsin L; D002403:Cathepsins / Q000037:antagonists & inhibitors* / Q000145:classification / Q000378:metabolism*; D003546:Cysteine Endopeptidases; D015853:Cysteine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D010450:Endopeptidases; D006801:Humans; D066298:In Vitro Techniques; D008247:Lysosomes / Q000201:enzymology*; D051379:Mice; D011730:Pyridoxal / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D015853:Cysteine Proteinase Inhibitors; D011730:Pyridoxal; D002403:Cathepsins; D010450:Endopeptidases; C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D003546:Cysteine Endopeptidases; C534281:CTSL protein, human; D056668:Cathepsin L; C534278:Ctsl protein, mouse; C534280:Ctsl protein, rat